The year's new drugs & biologics, 2013: Part II

Drugs of Today

Volumn 50, Issue 2, 2014, Pages 133-158

  Graul, A I ^a   Navarro, D ^a   Dulsat, G ^a   Cruces, E ^a   Tracy, M ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

Biosimilars; Breakthrough therapy designation; Discontinuations and withdrawals; Orphan drugs; Qualified infectious disease products

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; NEW DRUG; ORPHAN DRUG;

DRUG INDUSTRY; INFECTION; MERGERS AND ACQUISITIONS; PREDICTION; REVIEW; TREATMENT WITHDRAWAL;

BIOSIMILARS; BREAKTHROUGH THERAPY DESIGNATION; DISCONTINUATIONS AND WITHDRAWALS; ORPHAN DRUGS; QUALIFIED INFECTIOUS DISEASE PRODUCTS;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG INDUSTRY; DRUG THERAPY; HUMANS; ORPHAN DRUG PRODUCTION; PHARMACEUTICAL PREPARATIONS; PRODUCT RECALLS AND WITHDRAWALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84896094863     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.2.2122810     Document Type: Review

References (13)

1. Graul, A., Cruces, E., Stringer, M. The year's new drugs and biologics, 2013. Drugs Today (Barc) 2014, 50(1): 51-100.
2. The high cost of orphan drugs. Rare Disease Report 2013, published online July 31, 2013. http://www.raredr.com/articles/high-cost-orphan-drugs. Accessed February 1, 2014.
3. Morel, T., Popa, C., Simoens, S. Are orphan drug companies the pick of the pharmaceutical industry? Nat Rev Drug Discov 2014, 13(1): 10.
4. Picavet, E., Cassiman, D., Hollak, C.E., Maertens, J.A., Simoens, S. Clinical evidence for orphan medicinal products - A cause for concern? Orphanet J Rare Dis 2013, 8: 164.
5. Sherman, R.E., Li, J., Shapley, S., Robb, M., Woodcock, J. Expediting drug development - The FDA's new "breakthrough therapy" designation. N Engl J Med 2013, 369(20): 1877-80.
6. Walker, G. Breakthrough Therapy Designation: A new expedited approval pathway in the U.S. Thomson Reuters Forecast Market Insight, June 14, 2013.
7. Guidance for industry: Expedited programs for serious conditions - Drugs and biologics (U.S. Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research, June 2013). http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf. Accessed January 31, 2014.
8. Mullard, A. Learning from the 2012-2013 class of breakthrough therapies. Nat Rev Drug Discov 2013, 12(12): 891-3.
9. Goodman, J.L. Working together to address the challenges of rare and neglected diseases. Testimony before the Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations, Committee on Foreign Affairs, U.S. House of Representatives, June 27, 2013. http://www.fda.gov/ newsevents/testimony/ucm358834.htm. Accessed January 31, 2014.
10. Ogbighele, M. Biosimilar evolution - Current trends, challenges and future developments. Thomson Reuters Forecast Market Insight, May 3, 2013.
11. Bourgoin, A., Nuskey, B. An outlook on US biosimilar competition. Thomson Reuters White Paper, April 2013.
12. Mellstedt, H. Clinical considerations for biosimilar antibodies. EJC Supplements 2013, 11(3): 1.
13. Onyx deal expected to give Amgen a big boost. Reuters News (U.S. Edition), August 26, 2013. http://www.reuters.com/article/2013/08/26/us-onyx- amgen-idUSBRE97O0ES20130826. Accessed February 3, 2014.